Kiichiro Ninomiya

1.7k citations

81 papers · 715 indexed · h-index 16

Oncology top 5%
- Lung Cancer Research Studies 22
- Cancer Immunotherapy and Biomarkers 15
- HER2/EGFR in Cancer Research 9
- Colorectal Cancer Treatments and Studies 9
- Peptidase Inhibition and Analysis 5
- CAR-T cell therapy research 5
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations 44
- Lung Cancer Diagnosis and Treatment 9
Cancer Research
Pathology and Forensic Medicine
Radiology, Nuclear Medicine and Imaging

Co-authors: Katsuyuki Hotta Katsuyuki Kiura Eiki Ichihara Toshio Kubo Kadoaki Ohashi Yoshinobu Maeda Masahiro Tabata Takashi Ninomiya
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical Oncology (3 papers)SHILAP Revista de lepidopterología (1 paper)Cancer Research (6 papers)
Partner nations: Japan United States Netherlands

In The Last Decade

Kiichiro Ninomiya

69 papers receiving 705 citations

Peers

Countries citing papers authored by Kiichiro Ninomiya

Since Specialization

Citations

This map shows the geographic impact of Kiichiro Ninomiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiichiro Ninomiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiichiro Ninomiya more than expected).

Fields of papers citing papers by Kiichiro Ninomiya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kiichiro Ninomiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiichiro Ninomiya. The network helps show where Kiichiro Ninomiya may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kiichiro Ninomiya, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kiichiro Ninomiya Line = papers co-authored together Kiichiro Ninomiya links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	High Antigenicity for T_reg Cells Confers Resistance to PD‐1 Blockade Therapy via High PD‐1 Expression in T_reg Cells Cancer Science ·Hisae Matsuura,Takamasa Ishino,Toshifumi Ninomiya,Kiichiro Ninomiya,Kota Tachibana,Akiko Honobe‐Tabuchi,Yoshinori Muto,Takashi Inozume,Youki Ueda,Kadoaki Ohashi,Yoshinobu Maeda,Joji Nagasaki,Yosuke Togashi	2025	1
2	Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review International Journal of Clinical Oncology ·Takeshi Seta,Shohei Nakamura,Mitsuaki Oura,Kazuki Yokoyama,Yoshitaka Nishikawa,Nobuaki Hoshino,Kiichiro Ninomiya,Tatsunori Shimoi,Katsuyuki Hotta,Takeo Nakayama	2025	1
3	Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer Scientific Reports ·Tadahiro Kuribayashi,Rie Kinoshita,Kiichiro Ninomiya,Go Makimoto,Toshio Kubo,Kammei Rai,Eiki Ichihara,Katsuyuki Hotta,Masahiro Tabata,Yoshinobu Maeda,Katsuyuki Kiura,Shinichi Toyooka,Masakiyo Sakaguchi,Kadoaki Ohashi	2025	0
4	Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation Molecular Cancer Therapeutics ·Sachi Okawa,Shuta Tomida,Tadahiro Kuribayashi,Jun Nishimura,Takamasa Nakasuka,Atsuko Hirabae,Naofumi Hara,Hirofumi Inoue,Go Makimoto,Kiichiro Ninomiya,Kammei Rai,Eiki Ichihara,Katsuyuki Hotta,Masahiro Tabata,Yoshinobu Maeda,Katsuyuki Kiura,Kadoaki Ohashi	2025	0
5	Real‐World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma Cancer Medicine ·Eiji Nakata,Daisuke Ennishi,Tatsunori Osone,Kiichiro Ninomiya,Shuta Tomida,Takuto Itano,Tomohiro Fujiwara,Toshiyuki Kunisada,Naoyuki Ida,Hideki Yamamoto,Mashu Futagawa,Tatsunori Shimoi,Hiroyuki Yanai,Akira Hirasawa,Shinichi Toyooka,Masahiro Tabata,Toshifumi Ozaki	2025	1
6	Remarkable Efficacy of Capmatinib in a Patient with Cancer of Unknown Primary with <i>MET</i> Amplification Internal Medicine ·Takaaki Tanaka,Go Makimoto,Ryohei Sumii,Rika Omote,Yayoi Ando,Kiichiro Ninomiya,Eiki Ichihara,Kadoaki Ohashi,Yoshinobu Maeda,Masahiro Tabata	2025	0
7	Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines Lung Cancer ·Tatsuya Nishi,Ayako Morita,Naofumi Hara,Go Makimoto,Kiichiro Ninomiya,Masanori Fujii,Kammei Rai,Kadoaki Ohashi,Katsuyuki Hotta,Masahiro Tabata,Yosuke Togashi,Yoshinobu Maeda,Eiki Ichihara	2025	1
8	Phase II Study of Platinum Re-administration in Non-small Cell Lung Cancer Following Chemoimmunotherapy Resistance Cureus ·Kiichiro Ninomiya,Shinobu Hosokawa,Toshihide Yokoyama,Masaaki Inoue,Keisuke Sugimoto,Kenichiro Kudo,Toshiaki Okada,Tadashi Maeda,Haruyuki Kawai,Masayuki Yasugi,Koji Inoue,Shoichi Kuyama,Takashi Ninomiya,Isao Oze,Yoshinobu Maeda,Katsuyuki Hotta	2025	1
9	Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. Journal of Clinical Oncology ·Pasi A. Jänne,Yasushi Goto,Toshio Kubo,Kiichiro Ninomiya,Sang‐We Kim,David Planchard,Myung‐Ju Ahn,Egbert F. Smit,Adrianus J. de Langen,M. Pérol,Elvire Pons‐Tostivint,Silvia Novello,Hidetoshi Hayashi,Junichi Shimizu,Dong‐Wan Kim,Kaline Pereira,Fu-Chih Cheng,Ayumi Taguchi,Yingkai Cheng,Kōichi Goto	2024	4
10	Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report JCO Precision Oncology ·Kiichiro Ninomiya,Daisuke Ennishi,Kunio Okamoto,Midori Ando,Satoko Nakamura,Shuta Tomida,Yoshiyuki Ayada,Go Makimoto,Eiki Ichihara,Natsuko Okita,Shinichi Toyooka,Yoshinobu Maeda,Masahiro Tabata	2024	0
11	510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02) Annals of Oncology ·Yasushi Goto,Kōichi Goto,Toshio Kubo,Kiichiro Ninomiya,S-W. Kim,M-J. Ahn,Kazuhiko Nakagawa,Hidetoshi Hayashi,Junichi Shimizu,Dongwook Kim,J.C-H. Yang,C-H.S. Kuo,K.H. Lee,T-Y. Yang,Kaline Pereira,Ayumi Taguchi,Ahmed Ali,F-C. Cheng,Rie Yonemochi,Pasi A. Jänne	2023	2
12	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 Journal of Thoracic Oncology ·Pasi A. Jänne,Yasushi Goto,Toshio Kubo,Kiichiro Ninomiya,S.-W. Kim,D. Planchard,Myung‐Ju Ahn,Egbert F. Smit,Adrianus J. de Langen,M. Pérol,E. Pons-Tostivint,Silvia Novello,Hidetoshi Hayashi,Junichi Shimizu,D.-W. Kim,Karla Pereira,Fang Cheng,Ayumi Taguchi,Yun Cheng,Kōichi Goto	2023	2
13	Significance of the comprehensive geriatric assessment in the administration of chemotherapy to older adults with cancer: Recommendations by the Japanese Geriatric Oncology Guideline Committee Journal of Geriatric Oncology ·Kiichiro Ninomiya,Daisuke Inoue,Ken Sugimoto,Chie Tanaka,Keiko Nemoto Murofushi,Toru Okuyama,Shigeaki Watanuki,Chiyo K. Imamura,Daisuke Sakai,Naomi Sakurai,Kiyotaka Watanabe,Kazuo Tamura,Toshiaki Saeki,Hiroshi Ishiguro	2023	8
14	Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer Internal Medicine ·Takaaki Tanaka,Masataka Taoka,Go Makimoto,Kiichiro Ninomiya,Hisao Higo,Masanori Fujii,Eiki Ichihara,Kadoaki Ohashi,Katsuyuki Hotta,Masahiro Tabata,Yoshinobu Maeda	2023	4
15	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1- , or EGFR -altered Non–small Cell Lung Cancer Molecular Cancer Therapeutics ·Hirohisa Kano,Eiki Ichihara,Hiromi Watanabe,Kazuya Nishii,Chihiro Ando,Takamasa Nakasuka,Kiichiro Ninomiya,Yuka Kato,Toshio Kubo,Kammei Rai,Kadoaki Ohashi,Katsuyuki Hotta,Masahiro Tabata,Yoshinobu Maeda,Katsuyuki Kiura	2021	13
16	Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status Cancer Science ·Hirohisa Kano,Eiki Ichihara,Daijiro Harada,Koji Inoue,Hiroe Kayatani,Shinobu Hosokawa,Daizo Kishino,Kazuhiko Watanabe,Nobuaki Ochi,Naohiro Oda,Naofumi Hara,Kiichiro Ninomiya,Katsuyuki Hotta,Yoshinobu Maeda,Katsuyuki Kiura	2020	18
17	Pilot evaluation of a HER2 testing in non-small-cell lung cancer Journal of Clinical Pathology ·Katsuyuki Hotta,Hiroyuki Yanai,Kadoaki Ohashi,Kiichiro Ninomiya,Hiromi Nakashima,Hiroe Kayatani,Minoru Takata,Katsuyuki Kiura	2019	11
18	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403 Cancer Chemotherapy and Pharmacology ·Naohiro Oda,Kastuyuki Hotta,Kiichiro Ninomiya,Daisuke Minami,Eiki Ichihara,Toshi Murakami,Toshihide Yokoyama,Hirohisa Ichikawa,Kenichi Chikamori,Nagio Takigawa,Nobuaki Ochi,Shingo Harita,Yoshinobu Maeda,Katsuyuki Kiura	2018	20
19	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer Journal of Thoracic Oncology ·Katsuyuki Hotta,Keisuke Aoe,Toshiyuki Kozuki,Kadoaki Ohashi,Kiichiro Ninomiya,Eiki Ichihara,Toshio Kubo,Takashi Ninomiya,Kenichi Chikamori,Daijiro Harada,Naoyuki Nogami,Taizo Hirata,Shiro Hinotsu,Shinichi Toyooka,Katsuyuki Kiura	2017	123
20	Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non–Small-Cell Lung Cancer: Study Protocol Clinical Lung Cancer ·Kadoaki Ohashi,Katsuyuki Hotta,Taizo Hirata,Keisuke Aoe,Toshiyuki Kozuki,Kiichiro Ninomiya,Hiroe Kayatani,Hiroyuki Yanai,Shinichi Toyooka,Shiro Hinotsu,Minoru Takata,Katsuyuki Kiura	2016	16

About Kiichiro Ninomiya

Kiichiro Ninomiya is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Geriatrics and Gerontology, having authored 81 papers that have together received 715 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (22 papers), Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Diagnosis and Treatment (9 papers), HER2/EGFR in Cancer Research (9 papers), Colorectal Cancer Treatments and Studies (9 papers), Peptidase Inhibition and Analysis (5 papers) and CAR-T cell therapy research (5 papers). The work is most often cited by research in Oncology (512 citations), Pulmonary and Respiratory Medicine (474 citations) and Cancer Research (67 citations). Kiichiro Ninomiya has collaborated with scholars based in Japan, United States and Netherlands. Frequent co-authors include Katsuyuki Hotta, Katsuyuki Kiura, Eiki Ichihara, Toshio Kubo, Kadoaki Ohashi, Yoshinobu Maeda, Masahiro Tabata, Takashi Ninomiya, Daijiro Harada and Hiromi Watanabe. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact